Traders should monitor Enbumyst's commercial ramp-up, future milestone achievements, and integration into Esperion’s sales infrastructure. The acquisition significantly expands Esperion’s addressable market and could drive re-rating if sales meet expectations. Watch for commentary on profitability and cash runway during the March 3 conference call.
Price Chart
Executive Summary
Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, liver, and kidney disease. The deal includes a $75 million upfront cash payment, up to $180 million in potential milestone payments, and low double-digit royalties on future sales, with financing from existing credit facilities and royalty monetization. The acquisition expands Esperion’s cardiovascular portfolio and leverages its commercial infrastructure to target a U.S. market opportunity exceeding $4 billion.
Key Financial Metrics
Key Facts
- Esperion is acquiring Corstasis Therapeutics to add Enbumyst™ (bumetanide nasal spray) to its portfolio.
- Enbumyst is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for edema in CHF, hepatic, and renal disease.
- Deal includes $75 million upfront cash payment, up to $180 million in milestone payments, and low double-digit royalties on global sales.
- Transaction expected to close in Q2 2026, financed through existing credit facilities and royalty monetization with Athyrium and HealthCare Royalty.
- Enbumyst targets a U.S. market opportunity exceeding $4 billion, with potential expansion into nephrotic syndrome and other indications.
- Acquisition aligns with Esperion’s Vision 2040 and complements its established cardiovascular commercial platform.
Financial Impact
$75 million upfront cash outlay, $180 million in potential milestone payments, and royalty obligations; expected to accelerate double-digit revenue growth
Risk Factors
- Failure to achieve anticipated commercial uptake of Enbumyst
- Integration risks and execution challenges in scaling a new product
- Potential dilution or increased leverage from financing structure
- Forward-looking statements may not materialize as expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248116 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access